Elicio Therapeutics has achieved significant success with its peptide cancer vaccine, ELI-002, in Phase I trials by demonstrating a remarkable 77% reduction in the risk of death among patients with solid tumors, particularly pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer. By targeting the mutant-Kirsten rat sarcoma (mKRAS) antigen, the vaccine activates key immune cells’ anti-tumor mechanisms, showing an 88% reduction in the risk of relapse. Tumour biomarker responses were observed in 84% of patients, with complete biomarker clearance in 24% of cases.
The extended follow-up data revealed a median relapse-free survival (mRFS) of 16.33 months and an overall survival (OS) of 28.94 months, indicating the vaccine’s potential to offer long-lasting benefits. Patients who exhibited strong mKRAS-specific T-cell responses beyond a certain threshold showed the most significant benefits from ELI-002, with some patients not reaching the endpoints of mRFS or OS during follow-ups. These findings suggest that ELI-002 could trigger durable immune responses in patients with hard-to-treat solid tumors, providing hope for improved outcomes in these challenging indications.
Elicio’s stock value increased by 14.8% following the promising results, reflecting investor optimism in the vaccine’s potential. ELI-002, comprising a KRAS peptide antigen and an immune-stimulatory oligonucleotide, leverages the body’s T-cells to identify and eliminate cancer cells expressing mKRAS antigens. Through Elicio’s Amphiphile (AMP) platform, the vaccine efficiently delivers these components to lymph nodes, enhancing the adaptive immune system’s response against KRAS-mutated tumors across various solid tumor indications.
The National Cancer Institute estimates that KRAS mutations are prevalent in approximately one-third of all cancers, underscoring the importance of therapies targeting this protein. Although developing therapies against KRAS has been challenging due to its unique properties, promising late-stage candidates like Revolution Medicines’ daraxonrasib show potential for addressing KRAS mutations in cancers like PDAC. The emergence of mRNA-based cancer vaccines, such as autogene cevumeran, has also shown promise in early trials, although potential funding cuts to such projects could impact the sector’s advancement.
Elicio’s ELI-002 and other innovative therapies represent a significant step forward in cancer treatment, offering hope for patients with challenging malignancies. The success of ELI-002 in activating durable immune responses and improving survival outcomes underscores the potential of peptide-based therapeutics in revolutionizing cancer care. As research continues to advance in the field of cancer immunotherapy, novel approaches like ELI-002 hold promise for transforming the landscape of oncology treatment, providing new avenues for combating difficult-to-treat tumors.
Key Takeaways:
– Elicio Therapeutics’ peptide cancer vaccine, ELI-002, has shown a significant reduction in the risk of death and relapse in patients with solid tumors, particularly PDAC and colorectal cancer.
– The vaccine’s ability to trigger durable immune responses and improve survival outcomes highlights its potential in revolutionizing cancer treatment.
– Promising late-stage therapies targeting KRAS mutations and emerging mRNA-based cancer vaccines offer new avenues for addressing challenging malignancies.
– Funding cuts to mRNA vaccine projects may impact the sector’s advancement, potentially giving non-mRNA-based vaccines like ELI-002 a competitive edge in clinical development and market approval.
Read more on clinicaltrialsarena.com